(1Z)-N-hydroxy-4-phenylbenzenecarboximidoyl chloride | 1312032-82-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1Z)-N-hydroxy-4-phenylbenzenecarboximidoyl chloride
• CAS: 1312032-82-8
• 化学式: C₁₃H₁₀ClNO
• 分子量: 231.681
• InChiKey: NJTSANSJHYNRJE-SQFISAMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1Z)-N-hydroxy-4-phenylbenzenecarboximidoyl chloride 在 盐酸 、 三乙胺 、 copper dichloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 1.5h， 生成 2-([1,1′-biphenyl]-4-yl)-N-(2-(4-benzylpiperidin-1-yl)-2-oxoethyl)-2-oxoacetamide
  参考文献：
  名称：

  Reaction between (Z)-Arylchlorooximes and α-Isocyanoacetamides: A Procedure for the Synthesis of Aryl-α-ketoamide Amides

  摘要：

  (Z)-Arylchlorooximes and alpha-isocyanoacetamides undergo a smooth reaction to produce 1,3-oxazol-2-oxime derivatives in good yields. Opening of the oxazole ring and deoximation reaction give a facile access to aryl-alpha-ketoamide amides, a class of privileged scaffolds in medicinal chemistry and important synthetic intermediates in organic chemistry.

  DOI：

  10.1021/jo5005444
• 作为产物：
  描述：

  biphenyl-4-carbaldehyde oxime 在 N-氯代丁二酰亚胺 作用下， 生成 (1Z)-N-hydroxy-4-phenylbenzenecarboximidoyl chloride
  参考文献：
  名称：

  Reaction between (Z)-Arylchlorooximes and α-Isocyanoacetamides: A Procedure for the Synthesis of Aryl-α-ketoamide Amides

  摘要：

  (Z)-Arylchlorooximes and alpha-isocyanoacetamides undergo a smooth reaction to produce 1,3-oxazol-2-oxime derivatives in good yields. Opening of the oxazole ring and deoximation reaction give a facile access to aryl-alpha-ketoamide amides, a class of privileged scaffolds in medicinal chemistry and important synthetic intermediates in organic chemistry.

  DOI：

  10.1021/jo5005444

文献信息

• Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
  申请人：——

  公开号：US20040171651A1

  公开（公告）日：2004-09-02

  The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

  本发明涉及非甾体配体，用于核受体基于可诱导基因表达系统的使用，以及一种调节外源基因表达的方法，其中包括一个雌激素受体复合物：一个DNA结合结构域；一个配体结合结构域；一个转录激活结构域；和一个配体，与包括外源基因和响应元件的DNA构建物接触；其中外源基因受响应元件控制，DNA结合结构域与响应元件在配体存在的情况下结合导致基因的激活或抑制。
• 一种制备多取代的对醌甲基化螺环骨架类噁唑的方法
  申请人：首都医科大学

  公开号：CN114149378A

  公开（公告）日：2022-03-08

  本发明提供了一种制备多取代的对醌甲基化螺环骨架类噁唑的方法，通过该方法能够合成一系列多样性的具有式I所示的7,9‑二叔丁基‑3,4‑二苯基‑1‑氧杂‑2‑氮杂螺[4.5]十元‑2,6,9‑三烯‑8‑酮结构的衍生物。本发明的提出为构建的小分子化合物库，为后续的生物活性研究奠定了基础。同时，本发明的提出也为活性天然产物骨架的合成提供了新的技术手段。
• Isoxazole derivatives
  申请人：——

  公开号：US20040048908A1

  公开（公告）日：2004-03-11

  A compound represented by the formula (I) 1 wherein one of R 1 and R 2 is a hydrogen atom or a substituent and the other is an optionally substituted cyclic group; W is a bond or a divalent aliphatic hydrocarbon group; Y is a group of the formula: —OR 3 (wherein R 3 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group) or an optionally esterified or amidated carboxyl group, or a salt thereof or a prodrug thereof has a superior insulin secretion promoting action and a hypoglycemic action and shows low toxicity. Therefore, the compound is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of diabetes and diabetic complications, and the like.

  化合物的化学式为（I）1，其中R1和R2中的一个是氢原子或取代基，另一个是可选取代的环状基团；W是键或二价脂肪基碳氢基团；Y是式子：—OR3的基团（其中R3是氢原子、可选取代的碳氢基团、可选取代的杂环基团或可选取代的酰基基团），或可选酯化或酰胺化的羧基团，或其盐或前药。该化合物具有优异的促胰岛素分泌作用和降血糖作用，并且毒性低。因此，该化合物可用作制药剂，特别是用作糖尿病和糖尿病并发症的预防或治疗剂等。
• OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX
  申请人：Hormann Robert Eugene

  公开号：US20080255210A1

  公开（公告）日：2008-10-16

  The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

  本发明涉及非类固醇配体用于核受体诱导基因表达系统，并提供一种调节外源基因表达的方法，其中包括一个含有雌激素类固醇受体复合物的DNA结合域、配体结合域、转录激活域和配体的接触，与包含外源基因和响应元件的DNA构建物接触；其中，外源基因受响应元件控制，并在配体存在时DNA结合域与响应元件结合导致基因的激活或抑制。
• ISOXAZOLE DERIVATIVES
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1340749A1

  公开（公告）日：2003-09-03

  A compound represented by the formula (I) wherein one of R1 and R2 is a hydrogen atom or a substituent and the other is an optionally substituted cyclic group; W is a bond or a divalent aliphatic hydrocarbon group; Y is a group of the formula: -OR3 (wherein R3 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group) or an optionally esterified or amidated carboxyl group, or a salt thereof or a prodrug thereof has a superior insulin secretion promoting action and a hypoglycemic action and shows low toxicity. Therefore, the compound is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of diabetes and diabetic complications, and the like.

  由式（I）代表的化合物 其中 R1 和 R2 中的一个是氢原子或取代基，另一个是任选取代的环状基团； W 是键或二价脂族烃基； Y 是式中的一个基团：-OR3（其中 R3 是氢原子、任选取代的烃基、任选取代的杂环基或任选取代的酰基）或任选酯化或酰胺化的羧基，或其盐或其原药具有优异的促进胰岛素分泌作用和降血糖作用，且毒性低。因此，该化合物可用作药物制剂，特别是用于预防或治疗糖尿病和糖尿病并发症等。